Trial Profile
A Prospective, Observational, Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb (Fimasartan) During 1 Year Among 20 and Older Diagnosed With Essential Hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2019
Price :
$35
*
At a glance
- Drugs Fimasartan (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Boryung Pharmaceutical
- 16 Jan 2018 Planned End Date changed from 1 Sep 2017 to 1 Jun 2018.
- 25 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
- 25 Jul 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Sep 2017.